Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A large Swedish cohort study confirms that participating in fecal occult blood test (FOBT) screening significantly cuts colorectal cancer deaths. Among over 376,000 individuals tracked from 2008 to 2021, those who actually took part in screening saw a 43% reduction in CRC mortality. The message is simple: showing up for screening makes a real difference.
A major prospective cohort study out of Sweden's Karolinska Institutet, published in JAMA Network Open, adds powerful evidence to the case for colorectal cancer (CRC) screening. Researchers tracked over 376,000 individuals aged 60–69 across more than a decade, comparing those invited early to fecal occult blood test (FOBT) screening against a control group invited later or not at all.
The results were striking: simply being invited to screen was associated with a 26% reduction in CRC mortality. But actually participating in screening drove that number even further — a 43% reduction in mortality risk after adjusting for nonadherence and late-diagnosed cancers.
By the Numbers:
Why it matters: These findings reinforce that population-based CRC screening programs don't just look good on paper — they tangibly reduce deaths. Encouraging patient participation, not just program enrollment, should be a priority for clinicians and public health officials alike.
